v3.26.3
REVENUE AND COST OF SALES - Schedule of Disaggregated Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Disaggregation of Revenue [Line Items]        
Total net product sales $ 176,653 $ 179,516 $ 546,428 $ 529,538
Total net product sales        
Disaggregation of Revenue [Line Items]        
Total net product sales 175,436 178,040 543,305 525,981
EXPAREL        
Disaggregation of Revenue [Line Items]        
Total net product sales 142,510 139,902 433,607 419,348
ZILRETTA        
Disaggregation of Revenue [Line Items]        
Total net product sales 29,760 28,982 89,175 83,654
iovera°        
Disaggregation of Revenue [Line Items]        
Total net product sales 1,982 6,465 14,964 17,176
Bupivacaine liposome injectable suspension        
Disaggregation of Revenue [Line Items]        
Total net product sales $ 1,184 $ 2,691 $ 5,559 $ 5,803